Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan Plans Major Crackdown On Counterfeit Drugs

This article was originally published in PharmAsia News

Executive Summary

Taiwan authorities say they are about to launch a major effort to crack down on counterfeit drugs, backed by a series of nationwide raids

You may also be interested in...



Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel